Correlation of acetylator phenotype with peripheral, autonomic and central neuropathy in Northern Indian non-insulin-dependent diabetes mellitus patients

European Journal of Clinical Pharmacology

Volumn 55, Issue 6, 1999, Pages 419-424

  Misra, A ^a   Mittal, V ^a   Jain, S ^a   Bajaj, J S ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Acetylator phenotype; Central neuropathy; Non insulin dependent diabetes mellitus (NIDDM)

Indexed keywords

GLUCOSE; LIPID; SULFADIMIDINE;

ACETYLATOR PHENOTYPE; ADULT; ARTICLE; AUTONOMIC NEUROPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; EVOKED AUDITORY RESPONSE; EVOKED SOMATOSENSORY RESPONSE; FEMALE; GENETIC SUSCEPTIBILITY; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY FUNCTION TEST; LIPID BLOOD LEVEL; MALE; NERVE CONDUCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL;

ADULT; ARYLAMINE N-ACETYLTRANSFERASE; AUTONOMIC NERVOUS SYSTEM DISEASES; CENTRAL NERVOUS SYSTEM DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; EVOKED POTENTIALS, AUDITORY; EVOKED POTENTIALS, SOMATOSENSORY; HUMANS; INDIA; KIDNEY FUNCTION TESTS; MIDDLE AGED; MOTOR NEURONS; NEURAL CONDUCTION; NEURONS, AFFERENT; PERIPHERAL NERVOUS SYSTEM DISEASES; PHENOTYPE;

EID: 0032773291     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050650     Document Type: Article

References (37)

1. Devdetta S, Gangadharam PRJ, Andrews RH, Fox W, et al. (1960) Peripheral neuritis due to isoniazid. Bull World Health Organ 23: 587
2. McLaren EH, Burden AC, Moorhead PJ (1977) Acetylator phenotype in diabetic neuropathy. BMJ 2: 291-329
3. Clark DW (1985) Genetically determined variability in acetylation and oxidation. Therapeutic implications. Drugs 29: 342-375
4. Siegmund W, Franke G, Meng S, Gothe P, Meng W (1988) N-acetylator phenotype in hyperthyroidism. Int J Pharmacol Ther Toxicol 26: 397-399
5. Hardingham JE, Butler WJ, Roder D, Dobrovic A, Dymock RB, Sage RE, Roberts-Thomson IC (1998) Somatic mutations, acetylator status, and prognosis in colorectal cancer. Gut 42: 669-672
6. Hanke J, Krajewska B (1990) Acetylation phenotypes and bladder cancer. J Occup Med 32: 917-918
7. Martinez C, Agundez JA, Olivera M, Martin R, Ladero JM, Benitez J (1995) Lung cancer and mutations at the polymorphic NAT2 gene locus. Pharmacogenetics 5: 207-214
8. Bodansky HJ, Drury PL, Cudworth AG, Evans DAP (1981) Acetylator phenotype and type I (insulin-dependent) diabetics with microvascular disease. Diabetes 30: 907-910
9. Burrows AW, Hockaday TDR, Mann JI, Taylor JG (1978) Diabetic dimorphism according to acetylator status. BMJ 1: 208-210
10. Stryjek-Kaminska I, Malczewski B, Kopec A, Rowinska-Marcinska K (1988) Acetylator phenotype in diabetes mellitus. Acta Diabetol 25: 41-48
11. Thom S, Farrow PR, Santoso B, Alberti KGMM, Rawlins MD (1981) Effects of oral glucose on isoniazid kinetics. Br J Clin Pharmacol 11: 423
12. Hombhanje F (1990) An assessment of acetylator polymorphism and its relevance in Papua New Guinea. P N G Med 83: 107-110
13. Irshaid Y, Hadidi A, Abuirjeie M, Latif A, Sartawi O, Rawashdeh N (1992) Acetylator phenotypes of Jordanian diabetics. Eur J Clin Pharmacol 43: 623-631
14. Yazigi AE, Johansen K, Raines DA, Dossing M (1992) N-acetylation polymorphism and diabetes mellitus among Saudi Arabians. Clin Pharmacol 32: 905-910
15. Hussain SA, Mathur KG, Jhamaria JP (1973) Incidence of rapid and slow isoniazid inactivators with special reference to clinical response and toxicity of the drug amongst sputum positive pulmonary tuberculosis cases. Indian J Tuber 20: 20-22
16. Gupta RC, Nani CR, Jindal SK, Malik SK (1984) Incidence of isoniazid acetylation phenotypes in North Indians. Int J Clin Pharmacol Ther Toxicol 22: 259-264
17. Seth V, Seth SD, Beotra A, Singh U (1988) Comparison between serum INH levels and urinary sulfadimidine acetylation as predictors of INH acetylator status. Dev Pharmacol Ther 11: 32-36
18. Singh J, Arora A, Thakur VS, Tandon RK (1991) Predictors of antitubercular treatment induced hepatotoxicity (abstract). Indian J Gastroenterol 10: A5
19. Evans DAP (1969) An improved and simplified method of detecting the acetylator phenotype. J Med Genet 6: 405-407
20. DCCT Research Group (1997) Clustering of long term complications in the families with diabetes in Diabetes Complications and Control trial. Diabetes 46: 1829-1839
21. Heesom AE, Millward A, Demaine AG (1998) Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymorphism at the 5′ end of the aldose reductase gene. J Neurol Neurosurg Psychiatry 64: 213-216
22. Kitamura H, Moriyama T, Izumi M, Yokoyama K, Yamauchi A, Ueda N, Kamada T, Imai E (1996) Angiotensin I-converting enzyme insertion/deletion polymorphism: potential significance in nephrology. Kidney Int [Suppl 55]: S101-103
23. Alcolado JC, Baroni MG, Li SR, Galton DJ (1993) Genetic variation around the collagen IV Ia gene locus and proliferative retinopathy in type 2 diabetes mellitus. Hum Hered 43: 126-130
24. Barzilay J, Warram JH, Rand LI, Pfeifer MA, Krolewski AS (1992) Risk factor cardiovascular autonomic neuropathy is associated with the HLA-DR3/4 phenotype in type I diabetes mellitus. Ann Intern Med 116: 544-549
25. Mattila MJ, Tiitinen H (1976) The rate of isoniazid inactivation in Finnish diabetic and non-diabetic patients. Ann Med Exp Biol Fenn 45: 423-427
26. Shenfield GM, McCann VJ, Tjokresetio R (1982) Acetylator status and diabetic neuropathy. Diabetologia 22: 441-444
27. Agundez JA, Menaya JG, Tejeda R, Lago F, Chavez M, Benitez J (1996) Genetic analysis of the NAT2 and CYP2D6 polymorphisms in white patients with non-insulin-dependent diabetes mellitus. Pharmacogenetics 6: 465-472
28. Pontiroli AE, Calderara A, Bonisolli L, Maffi P, Margonato A, Radaelli G, Gallus G, Pozza G (1987) Risk factors for micro and macroangiopathic complications in type 2 diabetes: lack of association with acetylator phenotype, chlorpropamide alcohol flush and ABO and Rh blood groups. Diabetes Metab 13: 444-449
29. Madácsy L, Szórády I, S'anta A, V'amosi I (1992) Association of microalbuminuria with slow acetylator phenotype in type I diabetes mellitus. Child Nephrol Urol 12: 192-196
30. Gawronska-Szklarz B, Gornik W, Pawlik A, Kunicki P, Wojcicki J, Sitkiewicz D, Sych Z (1997) N-Acetylation and hydroxylation polymorphisms in type II diabetics with microvascular disturbances. Eur J Clin Pharmacol 51: 431-435
31. Rubini R, Biasiolo F, Fogarolo F, Magnavita V, Martini A, Fiori MG (1992) Brainstem auditory evoked potentials in rats with streptozotocin-induced diabetes. Diabetes Res Clin Pract 16: 19-25
32. Donald MW, Bird CE, Lawson JS, Lutemendia FJJ, et al. (1981) Delayed auditory brainstem responses in diabetes mellitus. J Neurol Neurosurg Psychiatry 44: 641-644
33. Nakamura Y, Takahashi M, Kitaguti M, Irnoka H, Kono N, Tarui S (1991) Abnormal brainstem evoked potentials in diabetes mellitus. Evoked potential testings and magnetic resonance imaging. Electromyogr Clin Neurophysiol 31: 243-249
34. Verma A, Bisht MS, Ahuja GK (1984) Involvement of central nervous system in diabetes mellitus. J Neurol Neurosurg Psychiatry 47: 414-416
35. Collier A, Reid W, McInnes A, Cull RE, et al. (1988) Somatosensory and visual evoked potentials in insulin dependent diabetics with mild peripheral neuropathy. Diabetes Res Clin Pract 5: 171-175
36. Aronson SM (1973) Intracranial vascular lesions in patients with diabetes mellitus. J Neuropathol Exp Neurol 32: 183
37. Dey J, Misra A, Desai NG, Mahapatra AK, Padma MV (1997) Cognitive functions in younger type II diabetics. Diabetes Care 20: 32-35